Navigation Links
ResearchDx Appointment of New Chief Medical Officer to Meet NIH Push for Precision Medicine in Expediting Bench to Bedside" Strategies for Disease Treatment
Date:12/7/2015

Internationally recognized as the "Contract Diagnostics Organization," ResearchDx specializes in the development of companion and in vitro diagnostics for the pharmaceutical, biotechnology, research, and diagnostic industries. To meet the demand for leveraging new technology and increase the speed at which new treatments reach patients, life sciences firm ResearchDx has appointed Shelly Gunn MD, PhD, FCAP as Chief Medical Officer and Medical Director of their CAP/CLIA certified clinical laboratory, Pacific Diagnostics.

Dr. Gunn's addition at ResearchDx and clinical laboratory, Pacific Diagnostics will expand the company's capabilities in the growing disciplines of Translational and Precision Medicine. Translational medicine aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Precision medicine is an emerging approach for disease prevention and treatments individualized to variations in each person’s genes, environment, and lifestyle. https://www.nih.gov/precision-medicine-initiative-cohort-program.

The National Institutes of Health (NIH) has made a major push to fund translational and precision medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools, and increasing the speed at which new treatments reach patients.

"I am delighted to be joining the globally recognized Contract Diagnostics Organization and look forward to working with the team in Irvine to promote continued excellence in the development of companion diagnostic assays for pharma, biotech, and the medical community. As Chief Medical Officer and Medical Director of our CAP/CLIA accredited laboratory, Pacific Diagnostics, I plan to rapidly translate new and innovative technologies from the research bench into clinically available patient testing for cancer, chronic disease, and wellness,” says Dr. Gunn.

A distinguished expert in molecular pathology, Dr. Gunn specializes in genomic biomarker identification for breast cancer and other solid tumors. Dr. Gunn’s Boards, Licensures, and Certifications include the American Board of Pathology, Certified in Clinical Pathology; Texas, New York, and California licensure, as well as a New York State Certificate of Qualification in Molecular and Cellular Tumor Markers.

For more information on the biopharma companion diagnostic test development process, translational, or precision medicine, please contact media representative Vicki Garcia at 619-660-6730.

Read the full story at http://www.prweb.com/releases/2015/11/prweb13094313.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related biology technology :

1. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
2. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
3. Appointment of Mr. Kevin Buchi to Benitec Board
4. Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
5. Taylor-Wharton™ Announces Recent Appointments in its Global Operations
6. Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
7. Emerson Resources Announces CEO Retirement and Appointment of Successor
8. Cellular Biomedicine Group Announces Appointment of Corporate Controller
9. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
10. inVentiv Health Clinical Expands and Strengthens Executive Team with Three Strategic Appointments
11. Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):